Literature DB >> 9667367

Natural porcine surfactant (Curosurf) down-regulates mRNA of tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha type II receptor in lipopolysaccharide-stimulated monocytes.

F M Baur1, B Brenner, B Goetze-Speer, S Neu, C P Speer.   

Abstract

We have previously shown that Curosurf, a natural porcine surfactant, and its phospholipids effectively suppressed secretion of tumor necrosis factor (TNF-alpha) by resting and through lipopolysaccharide (LPS)-stimulated human monocytes. In this study the effect of Curosurf on monocyte mRNA for TNF-alpha and TNF-alpha type II-receptor (TNF-alpha-RII) were analyzed to evaluate the cellular mechanisms involved in the modulation of TNF-alpha expression. LPS-stimulated monocytes simultaneously exposed to Curosurf (500 microg/mL for 24 h) expressed approximately 70% less TNF-alpha mRNA when compared with control subjects (p < 0.05). In addition, 86% less TNF-alpha RII mRNA was found in monocytes exposed to Curosurf (p < 0.001). Decreased mRNA expression was clearly associated with significantly reduced secretion of TNF-alpha protein (Curosurf-exposed LPS-stimulated monocytes 3628 +/- 1873 pg/mL TNF, LPS-stimulated monocytes 31,376 +/- 2524 pg/mL TNF; mean +/- SEM, p < 0.001). The activation of the transcription factor nuclear factor-kappaB upon LPS stimulation is not affected by Curosurf incubation. This excludes that the decrease in mRNA and protein levels of TNF-alpha and TNF-alpha-RII is due to an inhibition of nuclear factor-kappaB activation by Curosurf. We conclude that Curosurf affects TNF-alpha release of LPS-stimulated monocytes at a pretranslational site by down-regulating both mRNA for TNF-alpha and TNF-alpha-RII, therefore acting as an anti-inflammatory agent within alveolar space.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9667367     DOI: 10.1203/00006450-199807000-00005

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

Review 1.  Current perspectives on the drug treatment of neonatal respiratory distress syndrome.

Authors:  D G Sweet; H L Halliday
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

2.  Dipalmitoylphosphatidylcholine modulates inflammatory functions of monocytic cells independently of mitogen activated protein kinases.

Authors:  A Tonks; R H Morris; A J Price; A W Thomas; K P Jones; S K Jackson
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  Increased expression of ICAM-1 and VCAM-1 in the lung of nitrofen-induced congenital diaphragmatic hernia in rats.

Authors:  Kei Unemoto; Masato Sakai; Hideki Shima; Nino Guarino; Prem Puri
Journal:  Pediatr Surg Int       Date:  2003-05-21       Impact factor: 1.827

4.  Pulmonary surfactant coating of multi-walled carbon nanotubes (MWCNTs) influences their oxidative and pro-inflammatory potential in vitro.

Authors:  Michael Gasser; Peter Wick; Martin J D Clift; Fabian Blank; Liliane Diener; Bing Yan; Peter Gehr; Harald F Krug; Barbara Rothen-Rutishauser
Journal:  Part Fibre Toxicol       Date:  2012-05-24       Impact factor: 9.400

5.  Poractant alfa (Curosurf®) increases phagocytosis of apoptotic neutrophils by alveolar macrophages in vivo.

Authors:  Coen Hmp Willems; Florian Urlichs; Silvia Seidenspinner; Steffen Kunzmann; Christian P Speer; Boris W Kramer
Journal:  Respir Res       Date:  2012-03-09

6.  Impact of the New Generation Reconstituted Surfactant CHF5633 on Human CD4+ Lymphocytes.

Authors:  Markus Fehrholz; Kirsten Glaser; Silvia Seidenspinner; Barbara Ottensmeier; Tore Curstedt; Christian P Speer; Steffen Kunzmann
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

7.  Effects of the New Generation Synthetic Reconstituted Surfactant CHF5633 on Pro- and Anti-Inflammatory Cytokine Expression in Native and LPS-Stimulated Adult CD14+ Monocytes.

Authors:  Kirsten Glaser; Markus Fehrholz; Tore Curstedt; Steffen Kunzmann; Christian P Speer
Journal:  PLoS One       Date:  2016-01-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.